KANISHKA CHAKRABORTY
Allopathic & Osteopathic Physicians|Internal Medicine|Medical Oncology KINGSPORT, TN NPI 1992993760
Browse related groups: Allopathic & Osteopathic Physicians|Internal Medicine|Medical Oncology TN Daiichi Sankyo Inc. All categories
General Payments — all program years on this page
$1,382.39
- Category: General Payments
- Program years: PY2018–2024
- Record count: 64
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $1,292.71 across 58 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,232.19 | 55 |
| Education | $60.52 | 3 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| Daiichi Sankyo Inc. | $121.26 | 5 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $118.62 | 5 |
| Janssen Biotech, Inc. | $104.79 | 5 |
| BeiGene USA, Inc. | $88.09 | 4 |
| Merck Sharp & Dohme Corporation | $75.07 | 3 |
| PFIZER INC. | $71.98 | 3 |
| EISAI INC. | $65.30 | 3 |
| E.R. Squibb & Sons, L.L.C. | $58.78 | 3 |
| Takeda Pharmaceuticals U.S.A., Inc. | $50.25 | 2 |
| Incyte Corporation | $48.36 | 2 |
| Regeneron Healthcare Solutions, Inc. | $44.60 | 2 |
| Acerta Pharma LLC | $44.17 | 2 |
| Kyowa Kirin, Inc. | $41.35 | 2 |
| Gilead Sciences, Inc. | $40.51 | 2 |
| TAIHO ONCOLOGY, INC. | $39.09 | 2 |
| PUMA BIOTECHNOLOGY, INC. | $30.64 | 2 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $29.18 | 1 |
| Celgene Corporation | $27.84 | 1 |
| ABBVIE INC. | $25.96 | 1 |
| TerSera Therapeutics LLC | $23.92 | 1 |
| Lilly USA, LLC | $23.84 | 1 |
| Bayer HealthCare Pharmaceuticals Inc. | $22.56 | 1 |
| AVEO Pharmaceuticals, Inc. | $20.00 | 1 |
| Astellas Pharma US Inc | $19.68 | 1 |
| Myriad Genetic Laboratories, Inc. | $19.20 | 1 |
| Genentech USA, Inc. | $18.86 | 1 |
| ADC Therapeutics America, Inc. | $18.81 | 1 |
By program year
Records — PY2024 (58)
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.